If you have been reading about storage stability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-08. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Recent research has linked the rise in opioid-overdose deaths among Black Americans to the lack of safety, security, stability, and survival in their communities. Those missing pieces in these communities can be linked to a host of things including exposure to structural racism, lack of access to resources, and widespread mistrust in the healthcare system. Structural racism continues to have a lasting impact on predominantly Black communities in the United States. Racial segregation is one of the main forms of structural racism that has been linked to the increase in opioid-overdose related deaths among non-Hispanic Black Americans. Racial segregation does not only impact access to social and economic resources. It also has an impact on public health and disrupts access to health care. The impact that racial segregation has health care spills over to the access of substance use services. This leads to Black Americans having a more difficult time when seeking treatment for opioid use. Structural racism has also led to the consistent misdirection of funds and the over-funding of criminal legal systems within predominantly non-Hispanic Black communities. Instead of funding being used to improve substance abuse treatment and prevention, funds have been used to criminalize drugs and impose harsh penalties on Black community members. The policies put in place years ago have led to stereotyping and fear within Black communities that prevents Black Americans from seeking substance abuse treatment.
== Taxonomy == The first scientific description of D. cinnabari was made during a survey of Socotra led by Lieutenant Wellsted of the East India Company in 1835. It was first named Pterocarpus draco, but in 1880 the Scottish botanist Isaac Bayley Balfour made a formal description of the species and renamed it as Dracaena cinnabari. Of between 60 and 100 Dracaena species, D. cinnabari is one of only six species that grow as a tree. Along with other plants on Socotra, D. cinnabari is thought to have derived from the Tethyan flora. It is considered a remnant of the Mio-Pliocene Laurasian subtropical forests that are now almost extinct because of the extensive desertification of North Africa.
Trammell, SAJ; Schmidt, MS; Weidemann, BJ; Redpath, P; Jaksch, F; Dellinger, RW; Li, Z; Abel, ED; Migaud, ME; Brenner, C (10 October 2016). "Nicotinamide riboside is uniquely and orally bioavailable in mice and humans". Nature Communications. 7 (1) 12948. Bibcode:2016NatCo...712948T. doi:10.1038/ncomms12948. PMC 5062546. PMID 27721479. Trammell, SAJ; Weidemann, BJ; Chadda, A; Yorek, MS; Holmes, A; Coppey, LJ; Obrosov, A; Kardon, RH; Yorek, MA; Brenner, C (2016). "Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice". Scientific Reports. 6 26933. Bibcode:2016NatSR...626933T. doi:10.1038/srep26933. PMC 4882590. PMID 27230286. Wu, B-K; Brenner, C (2014). "Suppression of TET1-Dependent DNA Demethylation Is Essential for KRAS-Mediated Transformation". Cell Reports. 9 (5): 1827–1840. doi:10.1016/j.celrep.2014.10.063. PMC 4268240. PMID 25466250. Fagan, RL; Cryderman, DE; Kopelovich, L; Wallrath, LL; Brenner, C (2013). "Laccaic Acid A Is a Direct, DNA-competitive Inhibitor of DNA Methyltransferase 1". J. Biol. Chem. 288 (33): 23858–23867. doi:10.1074/jbc.M113.480517. PMC 3745332. PMID 23839987. Brenner, C (2013). "Changes in Chemistry and Biochemistry Education: Creative Responses to MCAT Revisions in the Age of the Genome". Biochemistry and Molecular Biology Education. 41 (1): 1–4. doi:10.1002/bmb.20653. PMID 23281187. S2CID 4659938. Brenner, C (2013). "Rethinking Premedical and Health Professional Curricula in Light of MCAT 2015" (PDF). J. Chem. Educ. 90 (7): 807–812. Bibcode:2013JChEd..90..807B. doi:10.1021/ed4002738. S2CID 98274150.
Sources: en.wikipedia.org
=== Legal basis in Germany === In Germany, the first X-ray regulation (RGBl. I p. 88) was issued in 1941 and originally applied to non-medical companies. The first medical regulations were issued in October 1953 by the Main Association of Industrial Employer's Liability Insurance Associations as accident prevention regulations for the Reich Insurance Code. Basic standards for radiation protection were introduced by directives of the European Atomic Energy Community (EURATOM) on February 2, 1959. The Atomic Energy Act of December 23, 1959 is the national legal basis for all radiation protection legislation in the Federal Republic of Germany (West) with the Radiation Protection Ordinance of June 24, 1960 (only for radioactive substances), the Radiation Protection Ordinance of July 18, 1964 (for the medical sector) and the X-ray Ordinance of March 1, 1973. Radiation protection was formulated in § 1, according to which life, health and property are to be protected from the dangers of nuclear energy and the harmful effects of ionizing radiation and damage caused by nuclear energy or ionizing radiation is to be compensated. The Radiation Protection Ordinance sets dose limits for the general population and for occupationally exposed persons. In general, any use of ionizing radiation must be justified and radiation exposure must be kept as low as possible even below the limit values. To this end, physicians, dentists and veterinarians, for example, must provide proof every five years - by Section 18a (2) X-ray Ordinance.
The melting points of branched-chain alkanes can be either higher or lower than those of the corresponding straight-chain alkanes, again depending on these two factors. More symmetric alkanes tend towards higher melting points, due to enthalpic effects when they form ordered crystals, and entropic effects when they form disordered crystals (e.g. neopentane).
== Chain standards == Standards organizations (such as ANSI and ISO) maintain standards for design, dimensions, and interchangeability of transmission chains. For example, the following table shows data from ANSI standard B29.1-2011 (precision power transmission roller chains, attachments, and sprockets) developed by the American Society of Mechanical Engineers (ASME). See the references for additional information.
=== Characterization === Cox described Logan Roy as a "mysterious character in many ways. I have a lot of empathy for him. I think he's very misunderstood. I think he's a tragic figure", and compared him to Shakespeare's tragic kings, such as Henry IV. "Obviously there's Lear connotations, but it's also the father dealing with a child in his son Hal and not understanding him." David Rasche, who plays Karl Muller, suggested to Jesse Armstrong that his character became a confessor to Logan, "But I don't think Jesse wanted that. Jesse wanted Logan Roy, a man alone." Cox thinks of Logan as "quite Puritan [...] Logan's a bastard, but he's not an indecent bastard." On Logan's romantic relationships he has said "He clearly loves Marcia. There's this idea that he had this affair with Rhea, but I'm not sure that happened. Both Holly [Hunter] and I felt that hadn't actually happened, [...] The kids thinking they were having an affair was more them projecting", but also added that "he's not good at relationships at all. The female relationships in his life have been pretty disastrous". By the final season Cox noted that, Colin and Kerry, Logan's bodyguard and assistant respectively, were "the two people who matter to him most." Cox has expressed that he believes that Logan's greatest weakness was that "he loves his children desperately." In interviews with The New Yorker, Armstrong agreed with Cox that Logan loves his children, even if he had done "things which are antithetical to what most people would consider to be love."
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.